VEC.L Share News (VEC)

Vectura appoints AstraZeneca executive James Ward-Lilley as CEO

Respiratory drugs specialist Vectura said on Wednesday that it has appointed James Ward-Lilley as chief executive officer and director effective 1 October. He will succeed Dr Chris Blackwell, who as previously announced, leaves the company at the end of this month. Ward-Lilley joins the group from

Vectura Poaches New Chief Executive James Ward-Lilley From AstraZeneca

Vectura Group appoints AstraZeneca executive as CEO

June 24 (Reuters) - Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca executive James Ward-Lilley as chief executive officer effective Oct. 1. Ward-Lilley replaces Chris Blackwell, who will leave the company at the end of this month. Ward-Lilley is currently vice pr

Vectura Group Says Novartis Planning New Asthma Therapy

Vectura Begins Phase I VR942-1-001 Clinical Trial In Asthma

BROKER RATINGS SUMMARY: Deutsche Bank Cuts BHP Billiton To Hold

Thursday broker round-up

Barclays: JP Morgan Cazenove reiterates overweight and 285p target. StanChart: Goldman sachs reiterates neutral. St.James Place: Numis reiterates add and 1050p target. Hargreaves Lansdown: JP Morgan Cazenove reiterates neutral and raises target to 1,100p from 1,050p. UK Mail Group: RBC Capital re

BROKER RATINGS SUMMARY: Nomura Raises Vodafone To Neutral From Reduce

Vectura Touches 15-Month High As It Reports Maiden Net Profit

Vectura revenue jumps 59 pct, beats estimates

May 20 (Reuters) - Respiratory drugs specialist Vectura Group Plc reported a bigger-than-expected jump in full-year revenue as it raked in higher royalty payments and licensing revenue. The company, which develops and markets drugs for illnesses such as asthma and chronic obstructive pulmon

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead